A well-studied example is TNF inhibitors, which show higher relative risk for remission in males with RA (Atzeni et al, 2009) and higher incidence of adverse effects in females with RA, resulting in higher rates of discontinuation (Souto et al, 2016). This evidence concerns the gene TNF and rheumatoid arthritis.